The purpose of this study was to examine the effect of different levels of cigarette smoking on lipid peroxidation, glutathione enzymes and paraoxonase 1 (PON1) activity in a healthy population. The study included 130 subjects who were classified as mild (20 cigarettes daily, Group III, n=33) and never smokers (controls, Group IV, n=32). Malondialdehyde (MDA) levels, PON1 and erythrocyte glutathione enzyme activities were measured. MDA levels were significantly higher in smokers than never smokers (P<0.05 for Group I, P<0.001 for Group II and III). PON1 activity was significantly lower in heavy smokers (P<0.001). Glutathione peroxidase (GSH-Px) activity was significantly lower in the smokers (P<0.0001). Glutathione reductase (GR) activity was significantly higher in smokers (P<0.0001). MDA levels negatively correlated with PON1 and GSH-PX activities (P<0.01), whereas they positively correlated with GR activities (P<0.001). At every level, cigarette smoking is associated with increased lipid peroxidation and causes an impairment in antioxidant systems.

These results implicate that the prevalence of GERD in asthma and COPD are lower than in published reports in a tertiary referral center. These differences might be related to the characteristics of developing countries, increased consumption of powerful medications in GERD and pulmonary diseases, or methodological flaws in earlier studies.

Chronic obstructive pulmonary disease (COPD) is characterised by a chronic inflammatory process in the large and small airways, as well as in the lung parenchyma. Although the role of oral corticosteroids in the management of acute exacerbations of COPD is well documented, its role in stable COPD is not clear. We examined the anti-inflammatory effect of inhaled budesonide on the percentage of neutrophils and on interleukin-8 (IL-8) levels in bronchoalveolar lavage (BAL) and their correlation with spirometry and symptom scores. Twenty-six patients with stable COPD were randomised, in a double-blinded, placebo-controlled trial with either 800 microg of inhaled budesonide or placebo for a 6-month period. The budesonide-treated subjects had significant reductions in IL-8 levels in the BAL after therapy (mean+/-sem, 1.53+/-0.72 at baseline vs. 0.70+/-0.48 ng/ml at 6 months, P=0.004) and a reduction in the mean percentages of neutrophils (17.16+/-2.67% vs. 13.25+/-2.28% P=0.002). The improvement in sputum production was of borderline (P=0.058) significance but there was no improvement in lung function. In stable patients with COPD, treatment with inhaled budesonide for a period of 6 months has a positive effect on markers of lung inflammation, as assessed by reduction in percentage neutrophils and IL-8 concentration in BAL.

The aim of the study was to investigate the success of a smoking cessation program among the smoking relatives of patients with serious smoking-related disorders and to determine whether having a relative with such a disorder influences the rate of success of the program. The relatives of patients with chronic obstructive pulmonary disease (COPD) and lung cancer who wanted to quit smoking were included in the smoking cessation program (group I, n = 34). During the same period, the same number of subjects with relatives free of any smoking-related diseases were included as a control group (group II, n = 34). Intensive behavioral therapy and motivational support was given to all subjects. Nicotine replacement therapy was administered to 10 subjects (29.4%) in group I and 14 subjects (41.2%) in group II. The subjects were evaluated in the 1st, 2nd, 4th, 8th and 12th week and subsequently every 3 months for a year in the outpatient clinic and proactive telephone interviews were performed periodically. In group I, 23.5% of subjects had a relative with COPD, 61.8% had relatives with lung cancer, and 14.7% had relatives with both COPD and lung cancer. The rate of quitting smoking was 79.4 and 73.5% on the 15th day and 41.2 and 38.2% at the end of the 1st year in groups I and II, respectively (p > 0.05). We observed that having a relative with serious smoking-related disorders did not motivate smokers to quit smoking.